Kevin Koch, the President and CEO of Edgewise Therapeutics , Inc. (NASDAQ:EWTX), a biotechnology company with a market capitalization of $2.5 billion, recently executed a series of stock transactions, ...

Release Feb. 3 - Omega Therapeutics: With cash running low, the Novo Nordisk-partnered biotech has struck a deal with its founder Flagship Pioneering that could see it file for bankruptcy and lay ...

Relmada, which has turned to strategic options after scrapping two phase 3 trials in major depressive disorder (MDD), is ...

Crown Laboratories and its affiliate Reba Merger Sub will now pay for the shares, which will cost the company $314.6 million.

The Massachusetts-based biotech plans to use the funds to push its candidates into mid-stage clinical trials in a space ...

Of the 102 company launches or series A financings since October 2023, just nine had a woman at the helm, according to a ...

Equities researchers at Zacks Research lifted their Q4 2024 earnings estimates for Sarepta Therapeutics in a research note issued to investors on Monday, February 3rd. Zacks Research analyst S.

Drug developer Maze Therapeutics said on Monday it was targeting a valuation of up to $728.1 million in its New York initial ...

A Huntsville-based biotechnology company has secured $10 million in funding to begin the trial of a new way to deliver medication to advanced Parkinson’s disease patients.

With Northway Biotech’s expertise in biologics manufacturing, Mallia aims to enter the multi-billion-dollar alopecia market by delivering a safe and effective topical sCD83 treatment designed to ...

Shares in clinical-stage biotechnology company Cargo Therapeutics (CRGX) have plunged after it scrapped trials of a cancer ...

Oruka Therapeutics, Inc.’s ORKA share price has dipped by 12.84%, which has investors questioning if this is right time to buy.